Victoza

Medical Editor: John P. Cunha, DO, FACOEP Last updated on RxList: 9/14/2021
Victoza Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

What Is Victoza?

Victoza (liraglutide [rDNA origin]) is a GLP-1 analog indicated for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise, to improve glycemic control in adults.

What Are Side Effects of Victoza?

Common side effects of Victoza include:

Tell your doctor if you have serious side effects of Victoza including:

  • swelling or a lump in your throat,
  • hoarse voice,
  • trouble swallowing,
  • shortness of breath,
  • urinating less than usual or not at all,
  • weakness,
  • confusion,
  • increased thirst,
  • loss of appetite,
  • pounding heartbeats or fluttering in your chest,
  • swelling,
  • weight gain,
  • pancreatitis (severe pain in your upper stomach spreading to your back, nausea and vomiting, loss of appetite, fast heart rate),
  • signs of infection (such as fever, chills, sore throat, flu symptoms),
  • easy bruising or bleeding (nosebleeds, bleeding gums),
  • mouth sores, or
  • unusual weakness.

Dosage for Victoza

Victoza should be injected subcutaneously in the abdomen, thigh, or upper arm once daily at any time of day. The injection site and timing can be changed without dose adjustment.

What Drugs, Substances, or Supplements Interact with Victoza?

Patients should be advised that Victoza delays gastric emptying and may impact the absorption of concomitantly administered oral medications especially oral diabetes medications (Glucotrol, Metaglip, Amaryl, Avandaryl, Duetact, DiaBeta, Micronase, Glucovance, and others). Tell your doctor all medications and supplements you use.

Victoza During Pregnancy and Breastfeeding

There are no adequate and well-controlled studies of Victoza in pregnant women. Victoza should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known if Victoza passes into breast milk. The patient and her healthcare provider should decide if Victoza will be taken or if the patient will breastfeed instead. Patients should not do both without consulting their healthcare providers first. Abrupt withdrawal of Victoza may lead to nausea and vomiting.

Additional Information

Victoza (liraglutide [rDNA origin]) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

QUESTION

______________ is another term for type 2 diabetes. See Answer
Victoza Consumer Information

Get emergency medical help if you have signs of an allergic reaction: hives; fast heartbeats; dizziness; trouble breathing or swallowing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

  • racing or pounding heartbeats;
  • sudden changes in mood or behavior, suicidal thoughts;
  • dehydration symptoms--feeling very thirsty or hot, being unable to urinate, heavy sweating, or hot and dry skin;
  • low blood sugar--headache, hunger, sweating, irritability, dizziness, fast heart rate, and feeling anxious or shaky;
  • gallbladder or pancreas problems--sudden and severe pain in your upper stomach that may spread to your back, nausea, vomiting, fever, jaundice (yellowing of your skin or eyes); or
  • signs of a thyroid tumor--swelling or a lump in your neck, trouble swallowing, a hoarse voice, feeling short of breath.

Common side effects may include:

  • low blood sugar;
  • nausea, vomiting, stomach discomfort, loss of appetite;
  • diarrhea, constipation;
  • rash;
  • headache, dizziness; or
  • feeling tired.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Victoza (Liraglutide [rDNA] Injection)

SLIDESHOW

Type 2 Diabetes: Signs, Symptoms, Treatments See Slideshow
Victoza Professional Information

SIDE EFFECTS

The following serious adverse reactions are described below or elsewhere in the prescribing information:

  • Risk of Thyroid C-cell Tumors [see WARNINGS AND PRECAUTIONS]
  • Pancreatitis [see WARNINGS AND PRECAUTIONS]
  • Use with Medications Known to Cause Hypoglycemia [see WARNINGS AND PRECAUTIONS]
  • Renal Impairment [see WARNINGS AND PRECAUTIONS]
  • Hypersensitivity Reactions [see WARNINGS AND PRECAUTIONS]

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Common Adverse Reactions

The safety of VICTOZA in subjects with type 2 diabetes was evaluated in 5 glycemic control, placebocontrolled trials in adults and one trial of 52 weeks duration in pediatric patients 10 years of age and older [see Clinical Studies]. The data in Table 1 reflect exposure of 1673 adult patients to VICTOZA and a mean duration of exposure to VICTOZA of 37.3 weeks. The mean age of adult patients was 58 years, 4% were 75 years or older and 54% were male. The population was 79% White, 6% Black or African American, 13% Asian; 4% were of Hispanic or Latino ethnicity. At baseline the population had diabetes for an average of 9.1 years and a mean HbA1c of 8.4%. Baseline estimated renal function was normal or mildly impaired in 88.1% and moderately impaired in 11.9% of the pooled population.

Table 1 shows common adverse reactions in adults, excluding hypoglycemia, associated with the use of VICTOZA. These adverse reactions occurred more commonly on VICTOZA than on placebo and occurred in at least 5% of patients treated with VICTOZA. Overall, the type, and severity of adverse reactions in adolescents and children aged 10 years and above were comparable to that observed in the adult population.

Table 1: Adverse reactions reported in ≥ 5% of VICTOZA-treated patients

Placebo
N=661
Liraglutide 1.2 mg
N= 645
Liraglutide 1.8 mg
N= 1024
Adverse Reaction(%)(%)(%)
Nausea51820
Diarrhea41012
Headache71110
Nasopharyngitis8910
Vomiting269
Decreased appetite1109
Dyspepsia147
Upper Respiratory Tract Infection676
Constipation155
Back Pain345
Cumulative proportions were calculated combining studies using Cochran-Mantel-Haenszel weights.

In an analysis of placebo- and active-controlled trials, the types and frequency of common adverse reactions, excluding hypoglycemia, were similar to those listed in Table 1.

Other Adverse Reactions

Gastrointestinal Adverse Reactions

In the pool of 5 glycemic control, placebo-controlled clinical trials, withdrawals due to gastrointestinal adverse reactions, occurred in 4.3% of VICTOZA-treated patients and 0.5% of placebo-treated patients. Withdrawal due to gastrointestinal adverse events mainly occurred during the first 2-3 months of the trials.

Injection Site Reactions

Injection site reactions (e.g., injection site rash, erythema) were reported in approximately 2% of VICTOZAtreated patients in the five double-blind, glycemic control trials of at least 26 weeks duration. Less than 0.2% of VICTOZA-treated patients discontinued due to injection site reactions.

Hypoglycemia

In 5 adult glycemic control, placebo-controlled clinical trials of at least 26 weeks duration, hypoglycemia requiring the assistance of another person for treatment occurred in 8 VICTOZA-treated patients (7.5 events per 1000 patient-years). Of these 8 VICTOZA-treated patients, 7 patients were concomitantly using a sulfonylurea.

Table 2 Adult Incidence (%) and Rate (episodes/patient year) of Hypoglycemia in 26-Week Combination Therapy Placebo- controlled Trials

Placebo ComparatorVICTOZA Treatment
Add-on to
Metformin
Placebo + Metformin
(N = 121)
VICTOZA + Metformin
(N = 724)
Patient not able to self-treat00.1 (0.001)
Patient able to self-treat2.5 (0.06)3.6 (0.05)
Add-on to
Glimepiride
Placebo + Glimepiride
(N = 114)
VICTOZA + Glimepiride
(N = 695)
Patient not able to self-treat00.1 (0.003)
Patient able to self-treat2.6 (0.17)7.5 (0.38)
Not classified00.9 (0.05)
Add-on to
Metformin + Rosiglitazone
Placebo + Metformin +
Rosiglitazone

(N = 175)
VICTOZA + Metformin +
Rosiglitazone

(N = 355)
Patient not able to self-treat00
Patient able to self-treat4.6 (0.15)7.9 (0.49)
Not classified1.1 (0.03)0.6 (0.01)
Add-on to
Metformin + Glimepiride
Placebo + Metformin +
Glimepiride

(N = 114)
VICTOZA + Metformin +
Glimepiride

(N = 230)
Patient not able to self-treat02.2 (0.06)
Patient able to self-treat16.7 (0.95)27.4 (1.16)
Not classified00
“Patient not able to self-treat” is defined as an event requiring the assistance of another person for treatment.

In a 26-week pediatric placebo-controlled clinical trial with a 26-week open-label extension, 21.2% of VICTOZA treated patients (mean age 14.6 years) with type 2 diabetes, had hypoglycemia with a blood glucose <54 mg/dL with or without symptoms (335 events per 1000 patient years). No severe hypoglycemic episodes occurred in the VICTOZA treatment group (severe hypoglycemia was defined as an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions).

Papillary Thyroid Carcinoma

In glycemic control trials of VICTOZA, there were 7 reported cases of papillary thyroid carcinoma in patients treated with VICTOZA and 1 case in a comparator-treated patient (1.5 vs. 0.5 cases per 1000 patient-years). Most of these papillary thyroid carcinomas were <1 cm in greatest diameter and were diagnosed in surgical pathology specimens after thyroidectomy prompted by findings on protocol-specified screening with serum calcitonin or thyroid ultrasound.

Cholelithiasis and Cholecystitis

In glycemic control trials of VICTOZA, the incidence of cholelithiasis was 0.3% in both VICTOZA-treated and placebo-treated patients. The incidence of cholecystitis was 0.2% in both VICTOZA-treated and placebo-treated patients.

In the LEADER trial [see Clinical Studies], the incidence of cholelithiasis was 1.5% (3.9 cases per 1000 patient years of observation) in VICTOZA-treated and 1.1% (2.8 cases per 1000 patient years of observation) in placebo-treated patients, both on a background of standard of care. The incidence of acute cholecystitis was 1.1% (2.9 cases per 1000 patient years of observation) in VICTOZA-treated and 0.7% (1.9 cases per 1000 patient years of observation) in placebo-treated patients.

Laboratory Tests

Bilirubin

In the five glycemic control trials of at least 26 weeks duration, mildly elevated serum bilirubin concentrations (elevations to no more than twice the upper limit of the reference range) occurred in 4.0% of VICTOZA-treated patients, 2.1% of placebo-treated patients and 3.5% of active-comparator-treated patients. This finding was not accompanied by abnormalities in other liver tests. The significance of this isolated finding is unknown.

Calcitonin

Calcitonin, a biological marker of MTC, was measured throughout the clinical development program. At the end of the glycemic control trials, adjusted mean serum calcitonin concentrations were higher in VICTOZAtreated patients compared to placebo-treated patients but not compared to patients receiving active comparator. Between group differences in adjusted mean serum calcitonin values were approximately 0.1 ng/L or less. Among patients with pretreatment calcitonin <20 ng/L, calcitonin elevations to >20 ng/L occurred in 0.7% of VICTOZA-treated patients, 0.3% of placebo-treated patients, and 0.5% of active-comparator-treated patients. The clinical significance of these findings is unknown.

Lipase and Amylase

In one glycemic control trial in renal impairment patients, a mean increase of 33% for lipase and 15% for amylase from baseline was observed for VICTOZA-treated patients while placebo-treated patients had a mean decrease in lipase of 3% and a mean increase in amylase of 1%.

In the LEADER trial, serum lipase and amylase were routinely measured. Among VICTOZA-treated patients, 7.9% had a lipase value at any time during treatment of greater than or equal to 3 times the upper limit of normal compared with 4.5% of placebo-treated patients, and 1% of VICTOZA-treated patients had an amylase value at any time during treatment of greater than or equal to 3 times the upper limit of normal versus 0.7% of placebo-treated patients.

The clinical significance of elevations in lipase or amylase with VICTOZA is unknown in the absence of other signs and symptoms of pancreatitis [see WARNINGS AND PRECAUTIONS].

Vital Signs

VICTOZA did not have adverse effects on blood pressure. Mean increases from baseline in heart rate of 2 to 3 beats per minute have been observed with VICTOZA compared to placebo.

Immunogenicity

Consistent with the potentially immunogenic properties of protein and peptide pharmaceuticals, patients treated with VICTOZA may develop anti-liraglutide antibodies. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, the incidence of antibodies to liraglutide cannot be directly compared with the incidence of antibodies of other products.

Approximately 50-70% of VICTOZA-treated patients in five double-blind clinical trials of 26 weeks duration or longer were tested for the presence of anti-liraglutide antibodies at the end of treatment. Low titers (concentrations not requiring dilution of serum) of anti-liraglutide antibodies were detected in 8.6% of these VICTOZA-treated patients. Cross-reacting anti-liraglutide antibodies to native glucagon-like peptide-1 (GLP- 1) occurred in 6.9% of the VICTOZA-treated patients in the double-blind 52-week monotherapy trial and in 4.8% of the VICTOZA-treated patients in the double-blind 26-week add-on combination therapy trials. These cross-reacting antibodies were not tested for neutralizing effect against native GLP-1, and thus the potential for clinically significant neutralization of native GLP-1 was not assessed. Antibodies that had a neutralizing effect on liraglutide in an in vitro assay occurred in 2.3% of the VICTOZA-treated patients in the double-blind 52- week monotherapy trial and in 1.0% of the VICTOZA-treated patients in the double-blind 26-week add-on combination therapy trials.

Antibody formation was not associated with reduced efficacy of VICTOZA when comparing mean HbA1c of all antibody-positive and all antibody-negative patients. However, the 3 patients with the highest titers of antiliraglutide antibodies had no reduction in HbA1c with VICTOZA treatment.

In five double-blind glycemic control trials of VICTOZA, events from a composite of adverse events potentially related to immunogenicity (e.g., urticaria, angioedema) occurred among 0.8% of VICTOZA-treated patients and among 0.4% of comparator-treated patients. Urticaria accounted for approximately one-half of the events in this composite for VICTOZA-treated patients. Patients who developed anti-liraglutide antibodies were not more likely to develop events from the immunogenicity events composite than were patients who did not develop anti-liraglutide antibodies.

In the LEADER trial [see Clinical Studies], anti-liraglutide antibodies were detected in 11 out of the 1247 (0.9%) VICTOZA-treated patients with antibody measurements.

Of the 11 VICTOZA-treated patients who developed anti-liraglutide antibodies, none were observed to develop neutralizing antibodies to liraglutide, and 5 patients (0.4%) developed cross-reacting antibodies against native GLP-1.

In a clinical trial with pediatric patients 10 to 17 years [see Clinical Studies], anti-liraglutide antibodies were detected in 1 (1.5%) VICTOZA treated patient at week 26 and 5 (8.5%) VICTOZA treated patients at week 53. None of the 5 had antibodies cross reactive to native GLP-1 or had neutralizing antibodies.

Post-Marketing Experience

The following additional adverse reactions have been reported during post-approval use of VICTOZA. Because these events are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

  • Medullary thyroid carcinoma
  • Dehydration resulting from nausea, vomiting and diarrhea.
  • Increased serum creatinine, acute renal failure or worsening of chronic renal failure, sometimes requiring hemodialysis.
  • Angioedema and anaphylactic reactions.
  • Allergic reactions: rash and pruritus
  • Acute pancreatitis, hemorrhagic and necrotizing pancreatitis sometimes resulting in death
  • Hepatobiliary disorders: elevations of liver enzymes, hepatitis

Read the entire FDA prescribing information for Victoza (Liraglutide [rDNA] Injection)

© Victoza Patient Information is supplied by Cerner Multum, Inc. and Victoza Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors